With box warnings

Without box warnings

Branded

Generic

2 results

selexipag
(Selexipag)
Zydus Lifesciences Limited
Usage: Selexipag tablets are indicated for treating pulmonary arterial hypertension (PAH, WHO Group I) to delay disease progression and reduce hospitalization risk. Effectiveness is established for patients with WHO Functional Class II-III symptoms, including idiopathic, heritable, and PAH associated with connective tissue disease or congenital heart defects.
uptravi
(Selexipag)
Actelion Pharmaceuticals US, Inc.
Usage: UPTRAVI is indicated for treating pulmonary arterial hypertension (PAH, WHO Group I) to delay disease progression and reduce hospitalization risk. Its efficacy was demonstrated in a long-term study involving patients with WHO Functional Class II–III PAH symptoms, including idiopathic, heritable, and connective tissue disease-related PAH.

Prostacyclin Receptor Agonist class drugs

selexipag